Linked Life Data

18312543

Source:http://linkedlifedata.com/resource/pubmed/id/18312543

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2008-5-16
pubmed:abstractText
Clinical trials and observations suggest that constipation is an uncommon side effect of treating overactive bladder with the muscarinic receptor antagonist tolterodine. Because muscarinic antagonism inhibits gastrointestinal motor activity, we evaluated the effects of tolterodine on bowel habits, gastrointestinal and colonic transit in healthy subjects. In this double-blind study, 36 healthy subjects were randomized to tolterodine extended release (ER, 4 mg daily) or placebo for 6 days. Gastric emptying (GE), small bowel and colonic transit were assessed on days 4-6 by scintigraphy. Bowel habits were recorded by diaries. Tolterodine did not significantly affect half-time for GE (GE t(half)) [116 +/- 6 min (mean +/- SEM) for placebo vs 126 +/- 7 min for tolterodine], small bowel transit measured by colonic filling at 6 h (45 +/- 6% for placebo vs 36 +/- 6% for tolterodine) or the geometric center of colonic transit at 24 h (2.9 +/- 0.2 for placebo vs 2.6 +/- 0.3 for tolterodine). Subjects who received tolterodine had slightly fewer bowel movements (i.e. 1.34 +/- 0.1 stools per day for placebo vs 1.0 +/- 0.1 for tolterodine; P = 0.02 for treatment effect). Tolterodine did not significantly affect stool consistency or ease of defecation. At the therapeutic dose used to treat overactive bladder, tolterodine did not significantly affect gastrointestinal or colonic transit and had minor effects on bowel habits in healthy subjects. Further studies are necessary to elucidate whether these observations are explained by tolterodine effects at muscarinic receptors which stimulate and inhibit gastrointestinal motility.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
1365-2982
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
20
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
643-8
pubmed:meshHeading
pubmed:year
2008
pubmed:articleTitle
Effect of tolterodine on gastrointestinal transit and bowel habits in healthy subjects.
pubmed:affiliation
Clinical and Enteric Neuroscience Translational and Epidemiological Research Program (CENTER), Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA. bharucha.adil@mayo.edu
pubmed:publicationType
Journal Article, Comparative Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural